Olema Oncology's Upcoming Investor Conference Engagements
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a pioneering clinical-stage biopharmaceutical firm, is dedicated to innovating targeted therapies aimed at treating breast cancer effectively. The company has announced its presence at several notable investor conferences. These conferences present a remarkable opportunity for Olema to share its recent developments and engage with the investment community.
Key Investor Conferences
Olema will participate in the renowned H.C. Wainwright 3rd Annual BioConnect Investor Conference, scheduled for Tuesday at 4:30 p.m. ET. This event will be a fireside chat format, taking place in New York City. During this engagement, executives will share insights about the company's pioneering efforts in breast cancer treatment and discuss its strategic vision for the future.
Another significant event is the T.D. Cowen 6th Annual Oncology Innovation Summit, set for the following week on Tuesday at 5 p.m. ET. This virtual summit will also feature a fireside chat, allowing Olema to connect with investors and industry leaders remotely. The discussions are anticipated to focus on the innovative clinical trials Olema is conducting and their potential impact on the field of oncology.
Webcast Access and Recording Availability
Live webcasts and recordings of both presentations will be made available to the public, contingent upon permissions from the event hosts. Interested individuals can find these valuable resources located in the Events and Presentations section of Olema’s investor relations website. This accessibility highlights Olema's commitment to transparency and engagement with its stakeholders.
About Olema Oncology
At the heart of Olema Oncology's mission is its commitment to transforming the standard of care for patients afflicted with breast cancer and other endocrine-driven cancers. The company is advancing a robust pipeline of innovative therapies, capitalizing on its profound understanding of nuclear receptors and resistance mechanisms in cancer treatment.
One of Olema's flagship candidates, palazestrant (OP-1250), is notable for being a proprietary, orally available complete estrogen receptor (ER) antagonist and a selective ER degrader (SERD). Currently, it is undergoing evaluation in the Phase 3 clinical trial known as OPERA-01. Additionally, Olema is progressing the development of a potent KAT6 inhibitor called OP-3136, which is hoped to contribute significantly to cancer management.
Headquartered in San Francisco, Olema also has operations in Cambridge, Massachusetts, reflecting its expansive reach in advancing biopharmaceutical innovations. For those eager to learn more about Olema's pipeline and initiatives, further details can be found on their official website.
Contact Information for Media and Investor Relations
For inquiries, Courtney O’Konek serves as the Vice President of Corporate Communications at Olema Oncology. Interested parties can reach out via email at media@olema.com to receive further information or clarification regarding Olema's research and investor relations.
Frequently Asked Questions
What conferences is Olema Oncology participating in?
Olema Oncology will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference and the T.D. Cowen 6th Annual Oncology Innovation Summit.
What is Olema Oncology known for?
Olema Oncology is focused on developing targeted therapies for breast cancer and other endocrine-driven cancers, with a commitment to improving patient outcomes.
Where can I find recordings of Olema's presentations?
Recordings of Olema's conference presentations will be available in the Events and Presentations section of Olema’s investor relations website.
What is palazestrant (OP-1250)?
Palazestrant (OP-1250) is an orally available estrogen receptor antagonist and selective estrogen receptor degrader currently in a Phase 3 clinical trial.
How can I contact Olema Oncology for more information?
You can reach out to Courtney O’Konek, Vice President of Corporate Communications, at media@olema.com for inquiries regarding corporate communication and investor relations.
